Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.22.28: picornain 3C

This is an abbreviated version!
For detailed information about picornain 3C, go to the full flat file.

Word Map on EC 3.4.22.28

Reaction

Selective cleavage of Gln-/-Gly bond in the poliovirus polyprotein. In other picornavirus reactions Glu may be substituted for Gln, and Ser or Thr for Gly =

Synonyms

3C protease, 3C protein, 3C proteinase, 3C-like protease, 3C-protease, 3CL, 3cLpro, 3CP, 3Cpro, 3Cpro protease, Avihepatovirus 3C protease, coxsackievirus 3C proteinase, cysteine proteinase 3C, DHAV 3C protease, enterovirus 3C protease, EV71 3Cpro, foot-and-mouth protease 3C, HAC 3C, HAV 3C protease, HAV 3Cpro, hepatitis A virus 3C proteinase, HRV 3C protease, HRV 3Cpro, HRV type-14 3C protease, HRV16 3C protease, Human rhinovirus 3C protease, human rhinovirus type-14 3C protease, nonstructural 3 protease, NS3 protease, NS6 protease, P3C, picornain 3C, picornain-3C, picornaviral 3C protease, picornavirus endopeptidase 3C, poliovirus protease 3C, poliovirus proteinase 3C, protease 3C, proteinase, foot-and-mouth-disease virus, 3C, proteinase, picornavirus, 3C, proteinase, poliovirus, 3C, proteinase, rhinovirus, 3C, rhinovirus 3C protease, rhinovirus protease 3C, SAT-type 3C protease, Senecavirus A 3C protease, SV3CP, SVA 3Cpro, tomato ringspot nepovirus 3C-related protease

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.22 Cysteine endopeptidases
                3.4.22.28 picornain 3C

Inhibitors

Inhibitors on EC 3.4.22.28 - picornain 3C

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid
(2Z)-3-[4-oxo-2-(pyridin-3-yl)-1,4-dihydroquinolin-6-yl]prop-2-enoic acid
-
70% effect at 0.1 mM
(3S)-[N3-(acetyl-L-leucyl-L-alanyl)-N1-[3'-(N,N-dimethylamino)-3'-oxopropyl]-N1-(methylsulfonyl)]-1,3-diaminobutan-2-one
-
weak competitive
(3S)-[N3-(acetyl-L-leucyl-L-alanyl)-N1-[3'-(N,N-dimethylamino)-3'-oxopropyl]-N1-(p-methylphenylsulfonyl)]-1,3-diaminobutan-2-one
-
weak competitive
(3S)-[N3-(benzyloxycarbonyl)-N1-[3'-(N,N-dimethylamino)-3'-oxoprolyl]-N1-(methylsulfonyl)]-1,3-diaminobutan-2-one
-
weak competitive
(3S)-[N3-(benzyloxycarbonyl)-N1-[3'-(N,N-dimethylamino)-3'-oxopropyl]-N1-(p-methylphenylsulfonyl)]-1,3-diaminobutan-2-one
-
weak competitive, IC50: 0.075 mM
(4R,5R)-N-(1,3-benzothiazol-2-yl)-2,2-dimethyl-5-[(4-phenylpiperazin-1-yl)carbonyl]-1,3-dioxolane-4-carboxamide
-
82.47% inhibition at 0.1 mM; complete inhibition at 0.1 mM
(4R,5R)-N-(1,3-benzothiazol-2-yl)-2,2-dimethyl-5-[[4-(3-methylbenzyl)piperazin-1-yl]carbonyl]-1,3-dioxolane-4-carboxamide
-
78.74% inhibition at 0.1 mM; 84.20% inhibition at 0.1 mM
(4R,5R)-N-(1,3-benzothiazol-2-yl)-2,2-dimethyl-5-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl]-1,3-dioxolane-4-carboxamide
-
85.35% inhibition at 0.1 mM; 97.80% inhibition at 0.1 mM
(4R,5R)-N-(1,3-benzothiazol-2-yl)-5-[(4-benzylpiperazin-1-yl)carbonyl]-2,2-dimethyl-1,3-dioxolane-4-carboxamide
-
67.80% inhibition at 0.1 mM; 85.51% inhibition at 0.1 mM, molecular docking study using the HRV 3C protease structure, PDB ID 1CQQ
(4R,5R)-N-(1,3-benzothiazol-2-yl)-5-[[4-(2-cyanophenyl)piperazin-1-yl]carbonyl]-2,2-dimethyl-1,3-dioxolane-4-carboxamide
-
56.36% inhibition at 0.1 mM; complete inhibition at 0.1 mM
(4R,5R)-N-(1,3-benzothiazol-2-yl)-N'-[2-[(3-methoxyphenyl)amino]ethyl]-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxamide
-
99.91% inhibition at 0.1 mM
(4R,5R)-N-(1,3-benzothiazol-2-yl)-N'-[2-[(4-methoxyphenyl)amino]ethyl]-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxamide
-
85.22% inhibition at 0.1 mM
(4R,5R)-N4-(2-((3-methoxyphenyl)amino)ethyl)-2,2-dimethyl-N5-(naphthalen-2-yl)-1,3-dioxolane-4,5-dicarboxamide
-
80.56% inhibition at 0.1 mM
(4S)-4-(acetylamino)-N,N-dimethyl-5-oxopentanamide
-
hepatitis A virus
(5-bromopyridin-3-yl)methyl furan-2-carboxylate
-
67% inhibition at 10 microM inhibitor concentration
(E)-2-({2-acetyl-1-[3-(dimethylamino)-3-oxopropyl]hydrazinyl}carbonyl)-N-(2-phenylethyl)diazenecarboxamide
-
potent, irreversible inhibitors with IC50 values in the low micromolar range, probably act by adding the active site thiol to the azo moiety in a Michael fashion to give a covalent complex
(E)-5-chloropyridin-3-yl 3-(furan-2-yl)acrylate
-
83% inhibition at 10 microM inhibitor concentration, above 90% inhibition at 1 microM inhibitor concentration, 43% inhibition at 0.25 microM inhibitor concentration
1,3-Dibromoacetone
-
-
1,3-diphenyl-4-(4-carboxybenzylidene)pyrazol-5(4H)-one
1-(2-(2-oxo-4-phenyl-2H-chromen-7-yloxy)acetyl)-4-ethylthiosemicarbazide
1-(2-(2-oxo-4-phenyl-2H-chromen-7-yloxy)acetyl)-4-methylthiosemicarbazide
-
-
1-acetyl-L-prolyl-L-alanyl-N-[(2E,4S)-7-amino-1-(benzyloxy)-1,7-dioxohept-2-en-4-yl]-6-ammonio-L-norleucinamide
-
-
1-acetyl-L-prolyl-L-alanyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-3-(1H-imidazol-3-ium-2-yl)-L-alaninamide
-
-
1-acetyl-L-prolyl-L-alanyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-5-ammonio-L-norvalinamide
-
-
1-acetyl-L-prolyl-L-alanyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-N5-[amino(iminio)methyl]-L-ornithinamide
-
-
1-acetyl-L-prolyl-L-alanyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-N6-[amino(iminio)methyl]-L-lysinamide
-
-
1-acetyl-L-prolyl-L-alanyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]glycinamide
-
-
1-acetyl-L-prolyl-L-alanyl-N-[(2E,4S)-7-amino-1-[methoxy(methyl)amino]-1,7-dioxohept-2-en-4-yl]-6-ammonio-L-norleucinamide
-
-
1-acetyl-L-prolyl-L-alanyl-N1-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-L-glutamamide
-
-
1-acetyl-L-prolyl-L-alanyl-N6-acetyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-L-lysinamide
-
-
1-acetyl-L-prolyl-N-[(2S)-1-[[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]amino]-4-ammonio-1-oxobutan-2-yl]-L-alaninamide
-
-
1-acetyl-L-prolyl-N-[(2S)-1-[[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]amino]-4-[[amino(iminio)methyl]amino]-1-oxobutan-2-yl]-L-alaninamide
-
-
1-benzoylprolyl-L-alanyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-6-ammonio-L-norleucinamide
-
-
1-benzylprolyl-L-alanyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-6-ammonio-L-norleucinamide
-
-
1-[(4-methylphenyl)sulfonyl]prolyl-L-alanyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-6-ammonio-L-norleucinamide
-
-
13C-labeled beta-lactone
-
-
-
2,2'-dipyridyl disulfide
-
0.4 mM, complete inhibition
2-(2-oxo-4-phenyl-2H-chromen-7-yloxy)-N'-(1-(4-bromophenyl)ethylidene)acetohydrazide
-
enzyme binding and protein interactions analysis
2-(2-oxo-4-phenyl-2H-chromen-7-yloxy)-N'-(1-(4-chlorophenyl)ethylidene)acetohydrazide
2-(2-oxo-4-phenyl-2H-chromen-7-yloxy)-N'-(1-phenylethylidene)acetohydrazide
2-(2-oxo-4-phenyl-2H-chromen-7-yloxy)-N'-(2-oxoindolin-3-ylidene)acetohydrazide
-
-
2-(2-oxo-4-phenyl-2H-chromen-7-yloxy)-N'-(5-bromo-2-oxoindolin-3-ylidene)acetohydrazide
-
-
2-(2-oxo-4-phenyl-2H-chromen-7-yloxy)-N'-(5-chloro-2-oxoindolin-3-ylidene)acetohydrazide
-
-
2-(pyridin-3-yl)quinolin-4(1H)-one
-
35% effect at 0.1 mM
2-aminopyridin-3-yl furan-2-carboxylate
-
24% inhibition at 0.001 mM
2-carbamoylpyridin-3-yl furan-2-carboxylate
-
14% inhibition at 0.001 mM
2-chloropyridin-3-yl thiophene-2-carboxylate
-
11% inhibition at 10 microM inhibitor concentration
2-methylpyridin-3-yl thiophene-2-carboxylate
-
below 10% inhibition at 10 microM inhibitor concentration, below 10% inhibition at 1 microM inhibitor concentration
2-oxo-1,2-dihydroquinolin-4-yl furan-2-carboxylate
-
98% inhibition at 0.001 mM
2-pyridin-3-yl-1-thiophen-2-ylethanone
-
10% inhibition at 10 microM inhibitor concentration
2-[(2-oxo-4-phenyl-2H-chromen-7-yl)oxy]acetohydrazide
-
-
3-(benzylamino)-5-[1-N-hydroxyethanimidoyl]benzamide
-
-
3-(bromoacetyl)-5-(naphth-2-ylmethyl)benzamide
-
12% inhibition at inhibitor concentration of 100 nM, 39% inhibition at inhibitor concentration of 1 microM, 83% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
3-(bromoacetyl)benzamide
-
4% inhibition at inhibitor concentration of 100 nM, 23% inhibition at inhibitor concentration of 1 microM, 85% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
3-(chloroacetyl)-5-(naphth-2-ylmethyl)benzamide
-
25% inhibition at inhibitor concentration of 100 nM, 61% inhibition at inhibitor concentration of 1 microM, 81% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
3-(chloroacetyl)benzamide
-
-
3-(dibromoacetyl)-5-(naphth-2-ylmethyl)benzamide
-
-
3-(dibromoacetyl)benzamide
-
-
3-(dichloroacetyl)benzamide
-
-
3-(difluoroacetyl)-5-[(phenylcarbonyl)amino]benzamide
-
-
3-(difluoroacetyl)benzamide
-
-
3-(trifluoroacetyl)benzamide
-
no inhibition of 3CP
3-(trifluoroacetyl)benzonitrile
-
-
3-acetyl-5-(5,8-dihydronaphthalen-2-ylmethyl)benzamide
-
-
3-acetyl-5-(naphth-1-ylcarbamoyl)benzoic acid
-
-
3-acetyl-5-(phenylcarbamoyl)benzoic acid
-
-
3-acetyl-5-benzylbenzamide
-
-
3-acetylbenzamide
-
-
3-amino-6-([[(2S)-1-([(2S,3E)-5-ethoxy-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl]amino)-1-oxo-3-phenylpropan-2-yl]amino]oxy)-6-methyl-4-oxoheptanoic acid
-
-
3-benzyl-5-(bromoacetyl)benzamide
-
0% inhibition at inhibitor concentration of 100 nM, 30% inhibition at inhibitor concentration of 1 microM, 68% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
3-benzyl-5-(chloroacetyl)benzamide
-
14% inhibition at inhibitor concentration of 100 nM, 79% inhibition at inhibitor concentration of 1 microM, 91% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
3-benzyl-5-(dibromoacetyl)benzamide
-
14% inhibition at inhibitor concentration of 100 nM, 27% inhibition at inhibitor concentration of 1 microM, 75% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
3-benzyl-5-(difluoroacetyl)benzamide
-
-
3-carbamoylphenyl furan-2-carboxylate
-
5% inhibition at 0.001 mM
3-chloro-5-(furan-2-ylmethoxy)pyridine
-
below 10% inhibition at 10 microM inhibitor concentration
3-chlorophenyl furan-2-carboxylate
-
11% inhibition at 10 microM inhibitor concentration
3-phenyl-1-(3,4-dichlorophenyl)-4-(4-carboxybenzylidene)pyrazol-5(4H)-one
3-phenyl-1-(3-chlorophenyl)-4-(4-carboxybenzylidene)pyrazol-5(4H)-one
3-phenyl-1-(3-nitrophenyl)-4-(4-carboxybenzylidene)-pyrazol-5(4H)-one
3-phenyl-1-(4-chlorophenyl)-4-(4-carboxybenzylidene)-pyrazol-5(4H)-one
3-phenyl-1-(4-cyanophenyl)-4-(4-carboxybenzylidene)-pyrazol-5(4H)-one
3-phenyl-1-(4-fluorophenyl)-4-(4-carboxybenzylidene)pyrazol-5(4H)-one
3-phenyl-1-(4-methoxyphenyl)-4-(4-carboxybenzylidene)pyrazol-5(4H)-one
3-phenyl-1-(4-trifluoromethoxyphenyl)-4-(4-carboxybenzylidene)pyrazol-5(4H)-one
3-[N1-(acetyl-L-leucyl-L-alanyl-L-alanyl)-N2-(o-nitrophenyl-sulfenyl)hydrazino]-N,N-(dimethyl)propanamide
-
IC50: 0.1 mM, time-dependent inactivation of the enzyme due to disulfide bond formation with the active site cysteine thiol
3-[N1-(bromoacetyl)-N2-(acetyl-L-leucyl-L-alanyl-L-alanyl)hydrazino]-N,N-(dimethyl)propanamide
-
time-dependent irreversible inactivator
3-[N1-(chloroacetyl)-N2-(acetyl-L-leucyl-L-alanyl-L-alanyl)hydrazino]1-N,N-(dimethyl)propanamide
-
time-dependent irreversible inactivator
4-(bromoacetyl)isoindolin-1-one
-
-
4-acetylisoindolin-1-one
-
-
4-amino-7-([[(2S)-1-([(2S,3E)-5-ethoxy-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl]amino)-1-oxo-3-phenylpropan-2-yl]amino]oxy)-7-methyl-5-oxooctanoic acid
-
-
4-bromoisoindolin-1-one
-
-
4-chloromercuribenzenesulfonate
-
strong inhibition at 0.05 mM
4-oxo-2-(pyridin-3-yl)-1,4-dihydroquinoline-6-carbaldehyde
-
95% effect at 0.1 mM
4-oxo-2-(pyridin-3-yl)-1,4-dihydroquinoline-6-carbonitrile
-
50% effect at 0.1 mM
4-phenyl-7-[(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methoxy]-2H-chromen-2-one
-
-
4S-(3-benzo[1,3]dioxol-5-yl-acryloylamino)-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[(2H-chromene-3-carbonyl)amino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[(2methyl-5-phenylfuran-3-carbonyl)amino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[(6-bromo-2H-chromene-3-carbonyl)amino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[(6-chloro-2H-chromene-3-carbonyl)amino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[(6-methyl-naphthalene-2-carbonyl)amino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[(7-bromonaphthalene-2-carbonyl)amino]-5-(2-oxopyrrolidin-3S-yl)-pent-2-enoic acid ethyl ester
-
-
4S-[(naphthalene-2-carbonyl)amino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid
-
-
4S-[3-(2,5-dibromophenyl)acryloylamino]-5-(2-oxopyrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[3-(3-bromo-4-fluorophenyl)acryloylamino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[3-(3-bromo-4-methyl-phenyl)-acryloylamino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[3-(3-bromophenyl)acryloylamino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid ethyl ester
-
-
4S-[3-(6'-bromo-benzo[1,3]dioxol-5-yl)acryloylamino]-5-(2-oxopyrrolidin-3S-yl)pent-2-enoic acid
-
-
5-(bromoacetyl)-N-2-naphthylisophthalamide
-
5% inhibition at inhibitor concentration of 100 nM, 19% inhibition at inhibitor concentration of 1 microM, 80% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
5-(bromoacetyl)-N-phenylisophthalamide
-
8% inhibition at inhibitor concentration of 100 nM, 27% inhibition at inhibitor concentration of 1 microM, 86% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
5-(dibromoacetyl)-N-2-naphthylisophthalamide
-
-
5-(dibromoacetyl)-N-phenylisophthalamide
-
-
5-acetyl-N-(naphthalen-1-yl)benzene-1,3-dicarboxamide
-
-
5-acetyl-N-phenylbenzene-1,3-dicarboxamide
-
-
5-bromopyridin-3-yl (2E)-3-phenylprop-2-enoate
-
63% inhibition at 0.001 mM
5-bromopyridin-3-yl 3-phenylpropanoate
-
34% inhibition at 0.001 mM
5-bromopyridin-3-yl furan-2-carboxylate
-
most potent inhibitor, 90% inhibition at 0.001 mM
5-bromopyridin-3-yl furan-3-carboxylate
-
inhibition not detected at 10 microM inhibitor concentration, above 90% inhibition at 1 microM inhibitor concentration, 87% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 1,3-thiazole-4-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration, 85% inhibition at 1 microM inhibitor concentration, 37% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 1-benzofuran-2-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration, above 90% inhibition at 1 microM inhibitor concentration, below 10% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 1-benzothiophene-2-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration, 47% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 1-naphthoate
-
above 90% inhibition at 10 microM inhibitor concentration, 30% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 1H-benzo[d]imidazole-5-carboxylate
-
82% inhibition at 10 microM inhibitor concentration, 75% inhibition at 1 microM inhibitor concentration, 32% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 1H-benzo[d][1,2,3]triazole-5-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 1H-imidazole-4-carboxylate
-
33% inhibition at 10 microM inhibitor concentration, 47% inhibition at 1 microM inhibitor concentration, 34% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 1H-indole-2-carboxylate
-
80% inhibition at 10 microM inhibitor concentration, 58% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 1H-indole-3-carboxylate
-
13% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 1H-indole-5-carboxylate
-
87% inhibition at 10 microM inhibitor concentration, 60% inhibition at 1 microM inhibitor concentration, 22% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 1H-pyrazole-3-carboxylate
-
82% inhibition at 0.001 mM
5-chloropyridin-3-yl 1H-pyrazole-4-carboxylate
-
56% inhibition at 10 microM inhibitor concentration, 21% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 2,6-dichloro-5-fluoronicotinate
-
44% inhibition at 10 microM inhibitor concentration, 19% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 2-(diphenylmethyl)-4-ethoxy-1,3-oxazole-5-carboxylate
-
5% inhibition at 0.001 mM
5-chloropyridin-3-yl 2-benzyl-4-ethoxy-1,3-oxazole-5-carboxylate
-
5% inhibition at 0.001 mM
5-chloropyridin-3-yl 2-chlorobenzoate
-
above 90% inhibition at 10 microM inhibitor concentration, 67% inhibition at 1 microM inhibitor concentration, 23% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 2-methoxybenzoate
-
85% inhibition at 10 microM inhibitor concentration, 57% inhibition at 1 microM inhibitor concentration, below 10% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 2-methylbenzoate
-
82% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 2-naphthoate
-
23% inhibition at 10 microM inhibitor concentration, 35% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 2-nitrobenzoate
-
above 90% inhibition at 10 microM inhibitor concentration, 24% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 2-oxo-2H-chromene-3-carboxylate
-
75% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 3,4-dimethoxybenzoate
-
59% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 3-acetoxybenzoate
-
above 90% inhibition at 10 microM inhibitor concentration, 27% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 3-chlorobenzoate
-
29% inhibition at 10 microM inhibitor concentration, 50% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 3-methylbenzoate
-
63% inhibition at 10 microM inhibitor concentration, 32% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 3-methylthiophene-2-carboxylate
-
below 10% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 3-[4-(trifluoromethyl)phenyl]-3H-pyrrole-5-carboxylate
-
40% inhibition at 0.001 mM
5-chloropyridin-3-yl 4-(diethylamino)benzoate
-
64% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 4-(dimethylamino)benzoate
-
above 90% inhibition at 10 microM inhibitor concentration, above 90% inhibition at 1 microM inhibitor concentration, 20% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 4-(methylamino)benzoate
-
82% inhibition at 10 microM inhibitor concentration, below 10% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 4-aminobenzoate
-
above 90% inhibition at 10 microM inhibitor concentration, 26% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 4-chloro-2-hydroxybenzoate
-
above 90% inhibition at 10 microM inhibitor concentration, 59% inhibition at 1 microM inhibitor concentration, 10% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 4-ethoxy-2-(naphthalen-2-yl)-1,3-oxazole-5-carboxylate
-
34% inhibition at 0.001 mM
5-chloropyridin-3-yl 4-ethoxy-2-[(E)-2-phenylethenyl]-1,3-oxazole-5-carboxylate
-
87% inhibition at 0.001 mM
5-chloropyridin-3-yl 4-fluorobenzoate
-
above 90% inhibition at 10 microM inhibitor concentration, 45% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 4-hydroxy-7-(trifluoromethyl)quinoline-3-carboxylate
-
below 10% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 4-methoxybenzoate
-
85% inhibition at 10 microM inhibitor concentration; above 90% inhibition at 10 microM inhibitor concentration, 50% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 4-methylbenzoate
-
77% inhibition at 10 microM inhibitor concentration, 70% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 4-sulfamoylbenzoate
-
64% inhibition at 10 microM inhibitor concentration, 57% inhibition at 1 microM inhibitor concentration, below 10% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 5-(2-(trifluoromethyl)phenyl)furan-2-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration, below 10% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 5-(2-chloro-5-(trifluoromethyl)phenyl)furan-2-carboxylate
-
76% inhibition at 10 microM inhibitor concentration, 36% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl 5-(2-nitrophenyl)furan-2-carboxylate
-
37% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 5-(3-nitrophenyl)furan-2-carboxylate
-
Inhibition not detected at 10 microM, 1 microM and 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 5-(4-chloro-2-nitrophenyl)furan-2-carboxylate
-
40% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl 5-(4-chlorophenyl)furan-2-carboxylate
5-chloropyridin-3-yl 5-(4-methylphenyl)furan-2-carboxylate
-
79% inhibition at 0.001 mM
5-chloropyridin-3-yl 5-(4-nitrophenyl)furan-2-carboxylate
-
60% inhibition at 0.001 mM
5-chloropyridin-3-yl 5-bromofuran-2-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration, 54% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 5-methyl-3-phenylisoxazole-4-carboxylate
-
below 10% inhibition at 10 microM inhibitor concentration, below 10% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 5-methylthiophene-2-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration, 24% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 5-nitro-1H-pyrazole-3-carboxylate
-
54% inhibition at 10 microM inhibitor concentration, 69% inhibition at 1 microM inhibitor concentration, 53% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl 5-phenylfuran-2-carboxylate
-
80% inhibition at 0.001 mM
5-chloropyridin-3-yl benzoate
5-chloropyridin-3-yl benzo[d]thiazole-6-carboxylate
-
74% inhibition at 10 microM inhibitor concentration, 54% inhibition at 1 microM inhibitor concentration, 27% inhibition at 0.25 microM inhibitor concentration
5-chloropyridin-3-yl benzo[d][1,3]dioxole-5-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration, 11% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl biphenyl-4-carboxylate
-
39% inhibition at 10 microM inhibitor concentration, 23% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl cinnamate
-
above 90% inhibition at 10 microM inhibitor concentration, 53% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl cyclohexanecarboxylate
-
81% inhibition at 10 microM inhibitor concentration, 32% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl furan-2-carboxylate
5-chloropyridin-3-yl furan-3-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl isonicotinate
-
37% inhibition at 10 microM inhibitor concentration, 34% inhibition at 1 microM inhibitor concentration
5-chloropyridin-3-yl naphthalene-1-carboxylate
-
75% inhibition at 0.001 mM
5-chloropyridin-3-yl naphthalene-2-carboxylate
-
80% inhibition at 0.001 mM
5-chloropyridin-3-yl pyrazine-2-carboxylate
-
22% inhibition at 10 microM inhibitor concentration
5-chloropyridin-3-yl thiophene-2-carboxylate
5-methylpyridin-2-yl thiophene-2-carboxylate
-
12% inhibition at 10 microM inhibitor concentration
6-(bromoacetyl)isoindolyn-1-one
-
0% inhibition at inhibitor concentration of 100 nM, 25% inhibition at inhibitor concentration of 1 microM, 70% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
6-acetyl-2-(pyridin-3-yl)quinolin-4(1H)-one
-
25% effect at 0.1 mM
6-acetylisoindolin1-one
-
-
6-bromoisoindolin-1-one
-
-
6-chloropyridin-2-yl thiophene-2-carboxylate
-
16% inhibition at 10 microM inhibitor concentration
6-chloropyridin-3-yl 1H-pyrrole-2-carboxylate
-
92% inhibition at 10 microM inhibitor concentration, below 10% inhibition at 1 microM inhibitor concentration, below 10% inhibition at 0.25 microM inhibitor concentration
6-chloropyridin-3-yl thiophene-2-carboxylate
-
25% inhibition at 10 microM inhibitor concentration
6-methyl-2-nitropyridin-3-yl thiophene-2-carboxylate
-
14% inhibition at 10 microM inhibitor concentration
6-methylpyridin-2-yl thiophene-2-carboxylate
-
91% inhibition at 10 microM inhibitor concentration, below 10% inhibition at 1 microM inhibitor concentration
6-methylpyridin-3-yl thiophene-2-carboxylate
-
23% inhibition at 10 microM inhibitor concentration
7-((4-ethyl-5-thioxo-1,2,4-triazol-3-yl)methoxy)-4-phenyl-2H-chromen-2-one
-
-
7-((4-methyl-5-thioxo-1,2,4-triazol-3-yl)methoxy)-4-phenyl-2H-chromen-2-one
-
-
7-((5-(2-(diethylamino)ethylthio)-1,3,4-oxadiazol-2-yl)methoxy)-4-phenyl-2H-chromen-2-one
-
-
7-((5-(2-(dimethylamino)ethylthio)-1,3,4-oxadiazol-2-yl)methoxy)-4-phenyl-2H-chromen-2-one
-
-
7-((5-(2-morpholinoethylthio)-1,3,4-oxadiazol-2-yl)methoxy)-4-phenyl-2H-chromen-2-one
-
-
7-((5-(2-morpholinoethylthio)-4-ethyl-4H-1,2,4-triazol-3-yl) methoxy)-4-phenyl-2H-chromen-2-one
-
-
7-((5-(ethylamino)-1,3,4-thiadiazol-2-yl)methoxy)-4-phenyl-2H-chromen-2-one
-
-
7-((5-(methylamino)-1,3,4-thiadiazol-2-yl)methoxy)-4-phenyl-2H-chromen-2-one
-
-
7-(2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethoxy)-4-phenyl-2H-chromen-2-one
-
-
7-(2-phenylethyl)-2-(pyridin-3-yl)quinolin-4(1H)-one
-
100% effect at 0.1 mM
7-hydroxy-4-phenyl-2H-chromen-2-one
-
-
7-methoxy-2-(pyridin-3-yl)quinolin-4(1H)-one
-
below 10% effect at 0.1 mM
7-methyl-2-(pyridin-3-yl)quinolin-4(1H)-one
-
40% effect at 0.1 mM
7-[(4-amino-5-sulfanyl-4H-1,2,4-triazol-3-yl)methoxy]-4-phenyl-2H-chromen-2-one
-
-
7-[hydroxy(phenyl)methyl]-2-(pyridin-3-yl)quinolin-4(1H)-one
-
80% effect at 0.1 mM
acetyl-Ala-Ala-Ala-(N,N'-dimethylglutaminal)
-
-
acetyl-LEALFQ-ethylpropionate
-
-
acetyl-Leu-Ala-Ala N,N-dimethylglutamine fluoroketone
-
irreversible inactivator
acetyl-Leu-Ala-Ala-(N,N'-dimethylglutaminal)
-
-
acyclovir
AG7088
AL21-01
-
Agouron aldehydic compound, 8% inhibition at inhibitor concentration of 100 nM, 75% inhibition at inhibitor concentration of 1 microM, 92% inhibition at inhibitor concentration of 0.01 mM, 700 nM enzyme
-
ammonium trichloro (dioxoethylene-O,O')tellurate
-
-
Aprotinin
-
0.1 mM, 64% inhibition
benzyloxycarbonyl-Leu-Phe-(glutaminol)
-
-
benzyloxycarbonyl-Leu-Phe-L-(cyanomethyl-alaninal)
-
-
benzyloxycarbonyl-Leu-Phe-L-(N,N-dimethyl-glutaminyl)
-
-
benzyloxycarbonyl-Leu-Phe-L-(N-acetylamino-alaninal)
-
-
benzyloxycarbonyl-Leu-Phe-L-(N-benzoylamino-alaninal)
-
-
benzyloxycarbonyl-Leu-Phe-L-(N-butyloxycarbonylamino-alaninal)
-
-
benzyloxycarbonyl-Leu-Phe-L-(N-carbomethoxyamino-alaninal)
-
-
benzyloxycarbonyl-Leu-Phe-L-(N-formylamino-alaninal)
-
-
benzyloxycarbonyl-Leu-Phe-L-(N-isobutyrylamino-alaninal)
-
-
benzyloxycarbonyl-Leu-Phe-L-(N-propinylamino-alaninal)
-
-
benzyloxycarbonyl-Leu-Phe-L-glutaminal-hemiaminal
-
-
benzyloxycarbonyl-Leu-Phe-L-[(N-trifluoroacetyl)amino-alaninal]
-
-
benzyloxycarbonyl-Leu-Phe-L-[methional sulfoxide]
-
-
benzyloxycarbonyl-Leu-Phe-L-[N-(2-pyrrolidinone)-alaninal]
-
-
benzyloxycarbonyl-Leu-Phe-L-[N-(isoxazole-5-carbonyl)aminoalaninal]
-
-
benzyloxycarbonyl-Leu-Phe-L-[N-(N,N-dimethylcarbamoyl)amino-alaninal]
-
-
benzyloxycarbonyl-Leu-Phe-[(N-methylsulfonyl)amino-alaninal]
-
-
benzyloxycarbonyl-Leu-Phe-[N-(Me)Ac-amino-alaninal]
-
-
beta-lactones
-
-
-
bis-vinylic organotellurane
-
-
calpastatin
-
0.8 mM, 30% inhibition
-
chloro-telluroxetane
-
-
chymostatin
Cu2+
-
5 mM decreases protease activity remarkably relative to the level of activity before the extra cations were added
dimethyl 5-acetylbenzene-1,3-dicarboxylate
-
-
Elastinal
-
-
ethyl (2E)-3-[(2S,5S,14S)-2-(4-fluorobenzyl)-9-methyl-14-[[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino]-3,8,15-trioxo-1,4,9-triazacyclopentadecan-5-yl]prop-2-enoate
-
-
ethyl (2E,4S)-4-([(2S)-2-[3-[[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino]-2-oxopyridin-1(2H)-yl]pent-4-ynoyl]amino)-5-[(3R)-2-oxopyrrolidin-3-yl]pent-2-enoate
-
compound AG7404
ethyl (2E,4S)-4-([(2S)-2-[3-[[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino]-2-oxopyridin-1(2H)-yl]pent-4-ynoyl]amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
-
-
ethyl (2E,4S)-4-([N-[(benzyloxy)carbonyl]-L-phenylalanyl]amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
-
-
ethyl (2E,4S)-4-[(N-[5-[(tert-butoxycarbonyl)amino]-6-hydroxy-2-methyl-4-oxoheptan-2-yl]-L-phenylalanyl)amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
-
-
ethyl (2E,4S)-4-[(N6-acetyllysyl)amino]-7-amino-7-oxohept-2-enoate
-
-
ethyl (2E,4S)-4-[(tert-butoxycarbonyl)amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
-
-
ethyl (2E,4S)-4-[[N-(5-amino-6-hydroxy-2-methyl-4-oxohexan-2-yl)-L-phenylalanyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
-
most potent inhibitor
ethyl (2E,4S)-4-[[N-(5-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-6-hydroxy-2-methyl-4-oxoheptan-2-yl)-L-phenylalanyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
-
-
ethyl (2E,4S)-4-[[N-(tert-butoxycarbonyl)-L-phenylalanyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate
-
-
ethyl (2Z)-3-[4-oxo-2-(pyridin-3-yl)-1,4-dihydroquinolin-6-yl]prop-2-enoate
-
90% effect at 0.1 mM
ethyl 3-amino-5-[1-(hydroxyamino)ethyl]benzoate
-
-
ethyl 3-[4-oxo-2-(pyridin-3-yl)-1,4-dihydroquinolin-6-yl]propanoate
-
0% effect at 0.1 mM
ethyl 4-[2-(4-cinnamoyl)amino-1-oxo-3-phenyl]propylamino-5-(2-oxo-3-pyrrolidyl)-2-pentenoate
-
-
ethyl 4-[2-(tert-butoxycarbonyl)amino-1-oxo-3-phenyl]propylamino-5-(2-oxo-3-pyrrolidyl)-2-pentenoate
-
-
ethyl 4-[2-[3,4-(methylenedioxy)cinnamoyl]amino-1-oxo-3-phenyl]propylamino-5-(2-oxo-3-pyrrolidyl)-2-pentenoate
-
-
ethyl 4-[2-[4-(dimethylamino)cinnamoyl]amino-1-oxo-3-phenyl]propyl-amino-5-(2-oxo-3-pyrrolidyl)-2-pentenoate
-
-
ethyl [(2-oxo-4-phenyl-2H-chromen-7-yl)oxy]acetate
-
-
eukaryotic release factor 3
-
increasing concentrations of recombinant His-tagged eRF3 lead to partial inhibition of 3Cpro-proteolytic cleavage of poly(A) binding protein that increases modestly
-
furan-2-yl pyridine-3-carboxylate
-
above 90% inhibition at 10 microM inhibitor concentration
iodoacetamide
iodoacetic acid
-
0.4 mM, complete inhibition
LY338387
-
0.00022 mM, 19% inhibition
LY355455
-
0.00031 mM, 72% inhibition
LY362270
-
0.01 mM, 43% inhibition
methyl 3-benzamido-5-{2,2-difluoro-1-[(2-methoxyethoxy)methoxy]ethenyl}benzoate
-
-
methyl 3-benzyl-5-bromobenzoate
-
-
methyl 3-bromo-5-(5,8-dihydronaphthalen-2-ylmethyl)benzoate
-
-
methyl 3-bromo-5-{2,2-difluoro-1-[(2-methoxyethoxy)methoxy]ethenyl}benzoate
-
-
methyl methanethiosulfonate
-
almost complete inhibition at 0.05 mM
methyl-3-(benzylamino)-5-carbamoylbenzoate
-
-
methyl-3-amino-5-carbamoylbenzoate
-
-
methyl-3-carbamoyl-5-(dibenzylamino)benzoate
-
-
methyl-3-{2,2-difluoro-1-[(2-methoxyethoxy)methoxy]ethenyl}-5-{[(trifluoromethyl)sulfonyl]oxy}benzoate
-
-
N-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-[(2-oxo-4-phenyl-2H-chromen-7-yl)oxy]acetamide
-
-
N-(2-chloropyridin-3-yl)thiophene-2-carboxamide
-
below 10% inhibition at 10 microM inhibitor concentration
N-(5-chloropyridin-2-yl)thiophene-2-carboxamide
-
below 10% inhibition at 10 microM inhibitor concentration
N-(5-fluoropyridin-2-yl)thiophene-2-carboxamide
-
below 10% inhibition at 10 microM inhibitor concentration
N-(6-chloropyridin-3-yl)thiophene-2-carboxamide
-
19% inhibition at 10 microM inhibitor concentration
N-(benzyloxycarbonyl)-D-serine-beta-lactone
-
competitive reversible inhibitor
N-(benzyloxycarbonyl)-L-serine-beta-lactone
-
irreversible, inactivation of the enzyme occurs by nucleophilic attack of the cysteine thiol Cys172 at the beta-position of the oxetanione ring
N-(methylsulfonyl)-L-serine-beta-lactone
-
weak time-dependent inhibition
N-(phenethylsulfonyl)-D-serine-beta-lactone
-
irreversible
N-(phenethylsulfonyl)-L-serine-beta-lactone
-
reversible
N-(trans-beta-styrenesulfonyl)-D-serine-beta-lactone
-
reversible
N-(trans-beta-styrenesulfonyl)-L-serine-beta-lactone
-
reversible
N-acetyl-L-alpha-glutamyl-L-phenylalanyl-L-glutaminyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-L-leucinamide
i.e. Michael acceptor peptidyl inhibitor (MAPI). Irreversible inhibitor in which the natural polyprotein substrate recognition sequence is linked to a propenyl ethyl ester moiety (X). The catalytic cysteine at position 139 of the enzyme is rapidly modified by the inhibitor
N-acetyl-L-leucyl-alanyl-alanyl-(N,N-dimethyl)-glutamine-(1,4-dioxo-3,4-dihydro-1H-phthalazin-2-yl)methyl ketone
-
-
N-acetyl-L-leucyl-alanyl-alanyl-(N,N-dimethyl)-glutamine-fluoromethyl ketone
-
-
N-acetyl-L-leucyl-phenylalanyl-phenylalanyl-glutamate-fluoromethyl ketone
-
-
N-benzoyl-L-alanyl-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]-6-ammonio-L-norleucinamide
-
-
N-Cbz-L-serine beta-lactone
-
irreversible inhibitor, associated with His 102 of the enzyme
N-ethylmaleimide
-
almost complete inhibition at 0.05 mM
N-iodoacetyl-Val-Phe-amide
-
irreversible inhibitor, alkylates the active site cysteine 172
N-methyl-3-[4-oxo-2-(pyridin-3-yl)-1,4-dihydroquinolin-7-yl]propanamide
-
45% effect at 0.1 mM
N-methyl-4-oxo-2-(pyridin-3-yl)-1,4-dihydroquinoline-7-carboxamide
-
40% effect at 0.1 mM
N-Methylmaleimide
-
-
N-pyridin-2-ylthiophene-2-carboxamide
-
below 10% inhibition at 10 microM inhibitor concentration
N-pyridin-3-ylthiophene-2-carboxamide
-
below 10% inhibition at 10 microM inhibitor concentration
N-pyridin-3-ylthiophene-2-sulfonamide
-
below 10% inhibition at 10 microM inhibitor concentration
N-pyridin-4-ylthiophene-2-carboxamide
-
below 10% inhibition at 10 microM inhibitor concentration
N-[(2S)-1-oxo-3-[(3S)-2-oxopiperidin-3-yl]propan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]-4-(pentylamino)butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]-4-(phenylamino)butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]-4-(propan-2-ylamino)butan-2-yl]-4-fluoro-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
docking modeling
N-[(2S)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]-4-(propan-2-ylamino)butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]-4-(propylamino)butan-2-yl]-4-fluoro-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]-4-(propylamino)butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]-4-(phenylamino)butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]-4-(propan-2-ylamino)butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(benzylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(benzylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(butylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(butylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(cyclohexylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-4-fluoro-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(cyclohexylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(cyclohexylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-4-fluoro-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(dodecylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(hexylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(methylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-(tert-butylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-[(2-methylpropyl)amino]-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-[(4-methylphenyl)amino]-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-[(4-nitrophenyl)amino]-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S)-4-[(furan-2-ylmethyl)amino]-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N-[(2S,5S,14S)-2-(4-fluorobenzyl)-5-formyl-3,8,15-trioxo-1,4,9-triazacyclopentadecan-14-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(2S,5S,14S)-2-(4-fluorobenzyl)-5-formyl-9-methyl-3,8,15-trioxo-1,4,9-triazacyclopentadecan-14-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
crystal structure of 4 in complex with HRV2 3C protease (PDB ID 6FFS)
N-[(2S,5S,14S)-5-[azetidin-1-yl(oxo)acetyl]-2-(4-fluorobenzyl)-9-methyl-3,8,15-trioxo-1,4,9-triazacyclopentadecan-14-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(3S,12S,16S,17aS)-3-formyl-7-methyl-1,6,13-trioxo-16-phenylhexadecahydro-1H-pyrrolo[1,2-a][1,4,9]triazacyclopentadecin-12-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(4S,7S,10S,17aR)-7-(4-fluorobenzyl)-10-formyl-1,5,8,13-tetraoxohexadecahydro-1H-pyrrolo[1,2-a][1,4,8,11]tetraazacyclopentadecin-4-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-leucyl-N-[(2S)-1-(acetylamino)-3-oxopropan-2-yl]-4-fluoro-L-phenylalaninamide
-
-
N-[(5S,8S,11S)-8-(4-fluorobenzyl)-11-formyl-2,6,9,14-tetraoxooctadecahydropyrrolo[2,1-k][1,4,8,12]tetraazacyclohexadecin-5-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(5S,8S,11S,13E,17S)-8-(4-fluorobenzyl)-5-formyl-2,7,10-trioxo-16-oxa-1,6,9-triazabicyclo[15.2.1]icos-13-en-11-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(5S,8S,11S,13Z,19S)-8-(4-fluorobenzyl)-5-formyl-2,7,10-trioxo-18-oxa-1,6,9-triazabicyclo[17.2.1]docos-13-en-11-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(5S,8S,11S,17S)-8-(4-fluorobenzyl)-5-formyl-2,7,10,16-tetraoxo-1,6,9,15-tetraazabicyclo[15.2.1]icos-11-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(6S,9S,12S)-9-(4-fluorobenzyl)-12-formyl-1-methyl-3,7,10,15-tetraoxo-1,4,8,11-tetraazacyclopentadecan-6-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(7S,10S,13S)-10-(4-fluorobenzyl)-7-formyl-3-methyl-4,9,12-trioxo-3,8,11-triazabicyclo[12.3.1]octadeca-1(18),14,16-trien-13-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(7S,10S,13S)-10-(4-fluorobenzyl)-7-formyl-4,9,12-trioxo-3,8,11-triazabicyclo[12.3.1]octadeca-1(18),14,16-trien-13-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-[(benzyloxy)carbonyl]glycyl-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-isoleucinamide
-
-
N-[(benzyloxy)carbonyl]glycyl-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
-
N-[(benzyloxy)carbonyl]glycyl-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-norleucinamide
-
-
N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-Nalpha-[(2E)-3-phenylprop-2-enoyl]-L-phenylalaninamide
-
-
N2-(morpholin-4-ylcarbonyl)-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
-
-
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide
N6-(1-acetylprolylalanyl)-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]lysinamide
-
-
N6-(N-acetylalanyl)-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]lysinamide
-
-
N6-(N-acetylalanylprolylalanyl)-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]lysinamide
-
-
N6-(prolylalanyl)-N-[(2E,4S)-7-amino-1-ethoxy-1,7-dioxohept-2-en-4-yl]lysinamide
-
-
Na+
-
the enzyme is strongly inhibited by 200 mM Na+
Nalpha-(tert-butoxycarbonyl)-N-[(2S)-4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-4-fluoro-L-phenylalaninamide
-
-
Nalpha-[(2E)-3-(1,3-benzodioxol-5-yl)prop-2-enoyl]-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide
-
-
Nalpha-[(2E)-3-(4-chloro-2-fluorophenyl)prop-2-enoyl]-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide
-
-
Nalpha-[(2E)-3-(4-methylphenyl)prop-2-enoyl]-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide
-
-
Nalpha-[(2E)-4-(5-methyl-1,2-oxazol-3-yl)but-2-enoyl]-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide
-
-
Nalpha-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]-4-(propan-2-ylamino)butan-2-yl]-4-fluoro-L-phenylalaninamide
-
-
Nalpha-[(benzyloxy)carbonyl]-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide
-
-
Nalpha-{(2E)-3-[4-(dimethylamino)phenyl]prop-2-enoyl}-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide
-
-
PABP-interacting protein 2
-
increasing concentrations of 1-3 microg inhibit cleavage of poly(A) binding protein by 3Cpro in a dose-dependent manner
-
peptide-mimetic monofluoromethyl ketones
-
-
-
phenylmethylsulfonyl fluoride
-
-
PMSF
-
1.7 mM, 32% inhibition
poliovirus-encoded nonstructural polypeptide 2B
-
low but detectable activity
-
poliovirus-encoded nonstructural polypeptide 2BC
-
efficiently blocks 3Cpro activity
-
poliovirus-encoded nonstructural polypeptide 2C
-
efficiently blocks 3Cpro activity, inhibits 3Cpro-catalyzed cleavage of cellular transcription factors at Q-G sites in vitro
-
pyridin-2-yl thiophene-2-carboxylate
-
89% inhibition at 10 microM inhibitor concentration, 8% inhibition at 1 microM inhibitor concentration
pyridin-3-yl furan-2-carboxylate
-
8% inhibition at 0.001 mM
pyridin-3-yl thiophene-2-carboxylate
-
83% inhibition at 10 microM inhibitor concentration, 21% inhibition at 1 microM inhibitor concentration
pyridin-4-yl thiophene-2-carboxylate
-
below 10% inhibition at 10 microM inhibitor concentration, 10% inhibition at 1 microM inhibitor concentration
rupintrivir
TLCK
-
0.2 mM, 51% inhibition
Tos-Phe-CH2-Cl
-
-
vinyl sulfones
-
-
-
additional information
-